Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors.
Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. Delcath has received Fast Track for its use of melphalan in. Delcath has received a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in. Delcath was treating unresectable liver tumors.